Results of the trial found that monotherapy led to clinical benefit in 16.7% of patients, including complete and partial responses in renal cell carcinoma (RCC) patients.
Image Credit: Adobe Stock Images/Hero Design
Nimbus Therapeutics presented promising data from its Phase 1/2 clinical trial of NDI-101150, a novel HPK1 inhibitor, at the American Society of Clinical Oncology (ASCO) Annual Meeting. According to the company, the trial assessed the treatment as a monotherapy and in combination with pembrolizumab in adults with advanced solid tumors. Results taken from 44 patients in dose escalation cohorts and 15 in dose expansion cohorts found that monotherapy offered clinical benefit to 16.7% of patients, with three patients also maintaining a stable disease over six months. Additionally, six out of eight renal cell carcinoma (RCC) patients experienced stable disease or better, and biopsies showed enhanced CD8+ T cells and dendritic cell infiltration.1
“We are encouraged by these results being presented at ASCO and additional observations to date showing monotherapy clinical benefit and an acceptable safety profile of NDI-101150, further validating HPK1 as a differentiated next-generation immunotherapy target for people living with advanced solid tumors in need of new effective treatment options,” said Nathalie Franchimont, MD, PhD, chief medical officer, Nimbus, in a press release. “HPK1 inhibition is a promising therapeutic approach as it is shown to activate T cells, B cells and dendritic cells to mount a robust anti-tumor response, whereas currently approved checkpoint inhibitors activate T cells. NDI-101150 is a potent and highly selective HPK1 inhibitor that has the potential to achieve significant tumor growth inhibition and make a meaningful difference for patients.”
Back in October, Nimbus announced preliminary data from the Phase 1/2 study of NDI-101150. The data, which included 13 patients, showed promise in safety and efficacy. Monotherapy supported clinical benefits in three patients, with a complete response in a renal cell carcinoma patient and prolonged stable disease in the other two. Further, the patient that experienced a complete recovery was previously treated with a formulation of nivolumab, an immune checkpoint inhibitor antibody.2
“We’re pleased to share these first clinical data from our clinical trial of NDI-101150. We are encouraged by the preliminary efficacy we have seen thus far, which supports the potential of NDI-101150 to provide a meaningful therapeutic option for patients with solid tumors,” said Franchimont, in a press release. “HPK1 inhibition is an exciting approach because of its potential to activate not just T cells, as checkpoint inhibitors do, but also B cells and dendritic cells. We look forward to sharing future updates on NDI-101150, including data from ongoing combination cohorts and dose expansion cohorts.”
According to CIRM, solid tumors consist of brain, ovary, breast, colon and cancers of other tissues. They are also believed to divide in order to create the cells that produce the tumor.3
“Stem cell scientists are studying cancer stem cells from solid tumors in the lab to find ways of destroying them. If these cancer stem cells share characteristics that allow them to be destroyed by the same drug, then a single new drug could significantly improve cancer treatment for a range of different cancer types,” reports CIRM.
References
1. Nimbus Therapeutics Presents New Positive Monotherapy Phase 1/2 Clinical Data of HPK1 Inhibitor in Treatment of Advanced Solid Tumors at 2024 ASCO Annual Meeting. Nimbus Therapeutics. May 23, 2024. Accessed May 24, 2024. https://www.nimbustx.com/2024/05/23/nimbus-therapeutics-presents-new-positive-monotherapy-phase-1-2-clinical-data-of-hpk1-inhibitor-in-treatment-of-advanced-solid-tumors-at-2024-asco-annual-meeting/
2. Nimbus Therapeutics Presents Positive Preliminary Data from Clinical Trial of HPK1 Inhibitor in Solid Tumors at SITC Annual Meeting. Nimbus Therapeutics. October 31, 2023. Accessed May 24, 2024. https://www.nimbustx.com/2023/10/31/nimbus-therapeutics-presents-positive-preliminary-data-from-clinical-trial-of-hpk1-inhibitor-in-solid-tumors-at-sitc-annual-meeting/
3. Solid Tumor Fact Sheet. CIRM. Accessed May 24, 2024. https://www.cirm.ca.gov/our-progress/disease-information/solid-tumor-fact-sheet/
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.